trending Market Intelligence /marketintelligence/en/news-insights/trending/uvpgtcwuej4k8auypva1fq2 content esgSubNav
In This List

Halozyme appoints former Bristol-Myers exec to board

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Halozyme appoints former Bristol-Myers exec to board

Halozyme Therapeutics Inc., a San Diego-based biotechnology company, appointed Bernadette Connaughton to its board.

Connaughton most recently worked with Bristol-Myers Squibb Co. as an intercontinental president for a region that included China, Latin America, Central and Eastern Europe and the Middle East. In this role, she developed the commercialization strategy for a number of products, including Opdivo, Yervoy, Sprycel, Daklinza and Orencia.

Halozyme researches, develops and commercializes human enzymes and other drug candidates in the U.S. and Switzerland, and internationally.